Tingjie Guo
Assistant professor
- Name
- Dr. T. Guo
- Telephone
- 071 5274501
- t.guo@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0002-7892-6220
Tingjie Guo is an Assistant Professor in translational PK/PD and pharmacometrics. His research integrates quantitative modeling with experimental and clinical data to understand therapeutic exposure and response, with a major focus on central nervous system pharmacology and the PK/PD of novel therapeutic modalities.
More information about Tingjie Guo
PhD Candidates
News
-
During the next pandemic, this mathematical model will speed up the search for treatment -
Dutch Research Council Open Science Fund grants for five Leiden projects -
ENW grant from the Dutch Research Council (NWO): Reversing antimicrobial resistance using bacteriophage -
Grant Elise Mathilde Fund & LUF: Using virus to kill bacteria: design of innovative phage-antibiotic combination treatments to combat antimicrobial resistance
Research
My research focuses on translational PK/PD and pharmacometrics, with the aim of understanding therapeutic exposure and response and translating experimental and clinical findings into improved treatment strategies.
A major focus of my research is central nervous system pharmacology and drug development. I am particularly interested in how physiological and disease-related factors influence drug distribution, target-site exposure, and treatment response in the CNS. My current work focuses primarily on CNS infections and brain tumors, including the impact of the blood-brain barrier, inflammation, and disease pathophysiology on CNS PK/PD. More broadly, I aim to develop quantitative and experimental approaches that can be applied across CNS diseases and therapeutic areas.
My second research area focuses on the PK/PD of novel therapeutic modalities. I am particularly interested in therapies with complex and dynamic interactions with biological systems that challenge conventional PK/PD concepts. My current work focuses on bacteriophage therapy using quantitative models to characterize interactions between therapeutic agents, pathogens, and the host and to support rational treatment design.
My research integrates experimental pharmacology with quantitative modeling approaches, including pharmacometrics, PBPK, QSP, and Bayesian methods, to support translation from preclinical research to clinical application.
Education
I coordinate the PK/PD course in the BSc programme in Bio-Pharmaceutical Sciences and teach pharmacometrics, PK/PD, and quantitative methods at bachelor's and master's levels.
Background
I obtained my BSc and MSc in Pharmaceutical Sciences from Peking University in 2014 and 2016, respectively, followed by a PhD from Amsterdam UMC (Vrije Universiteit Amsterdam) in 2021. I started as an Assistant Professor at Leiden University in 2021.
Assistant professor
- LACDR
- Divisie Systems Pharmacology and Pharmacy
- Ming S., Lynch K., Mariager T., Bodilsen J., Nau R., Wijk R.C. van, Manson M.L., Lange E.C.M. de & Guo T. (2026), Toward optimal moxifloxacin dosing in tuberculous meningitis: a translational physiologically based pharmacokinetic modeling approach, European Journal of Pharmaceutical Sciences 220: 107478.
- Sun M., Manson M.L., Guo T. & Lange E.C.M. de (2026), LeiCNS-PK3.2: a physiologically based pharmacokinetic model framework for predicting intracellular concentrations of acyclovir and ganciclovir active metabolites, European Journal of Pharmaceutical Sciences 221: 107496.
- Beldjenna M., Guedj J., Hasselt J.G.C. van & Guo T. (2026), Assessing the impact of bacterial heterogeneity on bacteriophage population dynamics, Journal of Pharmacokinetics and Pharmacodynamics 53(2): 15.
- Guo Y., Guo T., Hasselt J.G.C. van & Zwep L.B. (2026), Copulas for covariate simulation in pharmacometrics, CPT: Pharmacometrics & Systems Pharmacology 15(4): e70242.
- Guo Y., Yin J., Aulin L.B.S., Ciofu O., Moser C., Upadhyay P.J., Høiby N., Wang H., Guo T. & Hasselt J.G.C. van (2026), Pharmacodynamic modeling of colistin and imipenem against in vitro Pseudomonas aeruginosa biofilms, Biofilm 12: 100387.
- Baars L.R., Gu M., Guo T. & Hasselt J.G.C. van (2026), Strain-dependent variability in pharmacodynamic interactions for phage-antibiotic combinations in Pseudomonas aeruginosa, International Journal of Antimicrobial Agents 67(10): 107895.
- Guo Y., Yin J., Yonucu S., Knibbe C.A.J., Guo T. & Hasselt J.G.C van (2025), Spatial pharmacokinetic and pharmacodynamic modeling in airway mucus, Clinical Pharmacokinetics 64: 1869-1883.
- Sun M., Manson M.L., Märtson A.., Bodilsen J., Lange E.C.M. de & Guo T. (2025), Revisiting acyclovir dosing for adult viral encephalitis using a full Bayesian LeiCNS PBPK modeling approach, Clinical Pharmacokinetics 64(9): 1413-1423.
- Mehta K.M., Guo T. & Graaf P.H. van der Hasselt J.G.C. van (2024), Model‐based dose optimization framework for bedaquiline, pretomanid, and linezolid for the treatment of drug‐resistant tuberculosis, British Journal of Clinical Pharmacology 90(2): 463-474.
- Zwep L.B., Guo T., Nagler T.W., Knibbe C.A.J., Meulman J.J. & Hasselt J.G.C. van (2024), Virtual patient simulation using copula modeling, Clinical Pharmacology & Therapeutics 115(4): 795-804.
- Mehta K.M., Balazki P., Graaf P.H. van der, Guo T. & Hasselt J.G.C. van (2024), Predictions of bedaquiline central nervous system exposure in patients with tuberculosis meningitis using physiologically based pharmacokinetic modeling, Clinical Pharmacokinetics 63: 657-668.
- Sun M.,Manson M.L., Guo T. & Lange E.C.M. de (2024), CNS viral infections—what to consider for improving drug treatment: a plea for using mathematical modeling approaches, CNS Drugs 38(5): 349-373.
- Guo Y., Guo T., Knibbe C.A.J., Zwep L.B. & Hasselt J.G.C. van (2024), Generation of realistic virtual adult populations using a model-based copula approach, Journal of Pharmacokinetics and Pharmacodynamics 51: 735-746.
- Fu Y., Snelder N., Guo T., Graaf P.H. van der & Hasselt J.G.C. van (2023), Evaluation of a cardiovascular systems model for design and analysis of hemodynamic safety studies, Pharmaceutics 15(4): 1175.
- Mehta K.M., Guo T., Graaf P.H. van der & Hasselt J.G.C. van (2023), Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling, Clinical Pharmacokinetics 62(3): 519-532.
- Guo T., Abdulla A., Koch B.C.P., Hassel J.G.C. van, Endeman H., Schouten J.A., Elbers P.W.G., Brüggeman R.J.M. & Hest R.M. (2022), Pooled population pharmacokinetic analysis for exploring ciprofloxacin pharmacokinetic variability in intensive care patients, Clinical Pharmacokinetics 61(6): 869-879.
- Liu F., Aulin L.B.S., Guo T., Krekels E.H.J., Moerland M., Graaf P.H. van der & Hasselt J.G.C. van (2022), Modelling inflammatory biomarker dynamics in a human lipopolysaccharide (LPS) challenge study using delay differential equations, British Journal of Clinical Pharmacology 88(12): 5420-5427.
- Mehta K.M., Guo T., Wallis R.S., Graaf P.H. van der & Hasselt J.G.C. van (2022), Quantitative systems pharmacology modeling framework of autophagy in tuberculosis: application to adjunctive metformin host-directed therapy, Antimicrobial Agents and Chemotherapy 66(8): e0036622.
- Zwep L.B., Duisters K.L.W., Jansen M., Guo T., Meulman J.J., Upadhyay P. & Hasselt J.G.C. (2021), Identification of high‐dimensional omics‐derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling, CPT: Pharmacometrics and Systems Pharmacology 10(4): 350-361.
- Guo T.J., Hest R.M. van, Zwep L.B., Roggeveen L.F., Fleuren L.M., Bosman R.J., Voort P.H.J. van der, Girbes A.R.J., Mathot R.A.A., Elbers P.W.G. & Hasselt J.G.C. van (2020), Optimizing predictive performance of bayesian forecasting for vancomycin concentration in intensive care patients, Pharmaceutical Research 37: 171.
- Bestuurder